On January 30, 2020 ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that the Company will host a conference call at 8:00 a.m. ET on Friday, February 14, 2020 to discuss its 2019 operating results (Press release, ImmunoGen, JAN 30, 2020, View Source [SID1234553717]). Management will also provide a brief update on the business.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information
To access the live call by phone, dial (877) 621-5803; the conference ID is 3989656. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the webcast, a replay of the call will be available at the same location.

On January 30, 2020 Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and RIKEN Innovation Co., Ltd. (HQ: Saitama, Japan; President and CEO: Yoshihiro Aburatani) reported that they have signed a partnership agreement to use the research results from National Research and Development Institute RIKEN (HQ: Saitama, Japan; President: Hiroshi Matsumoto) to jointly create new businesses and return benefits to society (Press release, Sysmex, JAN 30, 2020, View Source [SID1234553683]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this agreement, the companies aim to apply advanced and broad-ranging research results from RIKEN, a comprehensive research institution for the natural sciences. The objective is to create high-value testing and diagnostic technologies to resolve global medical issues and contribute to the realization of personalized medicine.

The healthcare issues faced by individual countries have grown more diverse in recent years, due to aging populations and the expansion of preventive medicine in developed countries, and the establishment of healthcare infrastructures in emerging markets. With IT and other technological innovations making industries increasingly borderless, it is important to respond to increasingly diverse healthcare needs, proactively collaborate with companies and research institutions that go beyond their industry boundaries, and conduct R&D activities leading to efficient and effective innovation and the creation of new business opportunities.

Sysmex has established an open innovation lab at Technopark (Nishi-ku, Kobe) to pursue collaboration with researchers in Japan and overseas. The Company is pursuing numerous joint research projects at global R&D centers and through its network of Group companies, centering on the development of new diagnostic applications. In these ways, Sysmex aims to acquire unique diagnostic technologies through open innovation with medical and research institutions in Japan and overseas.

As a wholly owned subsidiary of RIKEN, RIKEN Innovation is tasked with promoting collaboration between industry and academia that will quickly return value to society based on RIKEN’s research results. As Japan’s key comprehensive research institution for the natural sciences, RIKEN is involved in a broad range of research fields. By promoting the joint creation of businesses, RIKEN Innovation will leverage research results from diverse researchers engaged in fundamental and applied research. As a result, RIKEN Innovation aims to work together on a variety of measures that will help resolve issues faced by companies and society.

Sysmex and RIKEN Innovation have entered into a partnership agreement in the aim of leveraging RIKEN’s cross-disciplinary research results and Sysmex’s R&D knowhow related to diagnostic technologies to create new diagnostic technologies and new businesses that can be rolled out globally.

Based on this partnership agreement, the two companies will collaborate in searching for needs with a view to creating new diagnostic technologies, outlining diagnostic technology development themes, and building an R&D structure. The companies will pursue open innovation aimed at creating new businesses.

Going forward, by providing diagnostic technologies created under this agreement, Sysmex, RIKEN Innovation and RIKEN aim to create treatment opportunities for patients with diseases that have no established diagnostic methods and contribute to medical economy through more efficient healthcare.

On January 30, 2020 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported financial results for the fourth quarter and full year ended December 31, 2019 (Press release, Quest Diagnostics, JAN 30, 2020, View Source [SID1234553702]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We had a solid fourth quarter and ended the year by delivering record revenues, earnings and cash from operations," said Steve Rusckowski, Chairman, CEO and President. "Strong volume growth from expanded health plan network access, combined with outstanding execution of our Operational Excellence strategy, helped us offset significant reimbursement pressure.

"Quest is well positioned once again in 2020 to deliver on our commitment to grow revenues and earnings. We have a strong value proposition that supports health care’s triple aim of improving medical quality and the patient experience while reducing the cost of care. Our guidance for 2020 reflects our continued momentum, partially offset by yet another year of meaningful reimbursement pressure."

For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage
of net revenues, income from continuing operations attributable to Quest Diagnostics, and diluted EPS from continuing
operations, see note 2 of the financial tables attached below.

Beginning in 2019, the company has changed how it presents adjusted income measures to additionally exclude amortization
expense for all periods presented. We believe this presentation provides investors with additional insight to evaluate our
performance period over period and relative to competitors, as well as to analyze the underlying trends in our business.

Dividend and Share Repurchase Authority Increased

Quest Diagnostics’ Board of Directors authorized a 5.7% increase in its quarterly dividend from $0.53 to $0.56 per share, or $2.24 per share annually, payable on April 21, 2020 to shareholders of record of Quest Diagnostics common stock on April 7, 2020. This dividend increase is the company’s ninth since 2011.

The Board also increased the company’s share repurchase authorization by $1 billion, bringing the total authorization available to $1.2 billion as of December 31, 2019.

Guidance for Full Year 2020

The company estimates full year 2020 results as follows:

Note on Non-GAAP Financial Measures

As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, the gain associated with the sale and leaseback of a property, and other items.

Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

Conference Call Information

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: Investor; or via live webcast on the company’s website at www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-357-4210 for domestic callers or 203-369-0125 for international callers. No passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on January 30, 2020 until midnight Eastern Time on February 13, 2020. Anyone listening to the call is encouraged to read the company’s periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

On January 30, 2020 MedX Health Corp. ("MedX" or the "Company") (TSX-V:MDX) is reported that it has received Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 25,000,000 units at $0.12 per unit ("Unit"), to raise up to $3,000,000 (Press release, MedX Health, JAN 30, 2020, View Source [SID1234553718]). Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. Closing of the Placement, which will take place in tranches, will be subject to receipt of subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. Qualified Agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 8% of funds so introduced, and issuance of agent’s warrants ("Agent’s Warrant(s)") equal in number to 8% of the number of units so subscribed for. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.12 per Unit, at any time during the period of two years following the Closing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company further announces that on January 30, 2020, it closed a first tranche of the Private Placement by issuing a total of 1,485,000 Units, to raise $178,200 from accredited investors. The securities issued on January 30, 2020, will be restricted from trading for four months. In connection with this first Closing, a cash commission of $10,080 was paid and 84,000 Agent’s Warrants were issued. Following this first Closing, the Private Placement offering remains open for further subscriptions, subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange.

On January 30, 2020 Karolinska Development (Nasdaq Stockholm: KDEV) reported that its portfolio company Aprea Therapeutics has been granted Breakthrough Therapy Designation for APR-246 in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) with a TP53 mutation (Press release, Aprea, JAN 30, 2020, https://www.karolinskadevelopment.com/en/press-releases?page=/en/pressreleases/karolinska-development%2527s-portfolio-company-aprea-therapeutics-receives-fda-breakthrough-therapy-designation-1769167 [SID1234553684]). A Breakthrough Therapy Designation facilitates expedited development and regulatory review of a drug candidate.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

APR-246 is a small molecular drug candidate that binds, refolds and stabilizes mutant p53, occurring in approximately 50% of all human tumors. A pivotal Phase 3 clinical trial of APR-246 and azacitidine for frontline treatment of TP53 mutant MDS is ongoing. APR-246 has previously received Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the EMA for MDS, acute myeloid leukemia (AML) and ovarian cancer.

"This is yet another success for Aprea Therapeutics, and we look forward to following the continued development of its potentially ground-breaking cancer therapy", says Viktor Drvota, CEO, Karolinska Development AB, in response to the announcement.

MDS represents a spectrum of hematopoietic stem cell malignancies in which bone marrow fails to produce sufficient numbers of healthy blood cells. Approximately 30-40% of MDS patients progress to acute myeloid leukemia (AML) and mutation of the p53 tumor suppressor protein is thought to directly contribute to disease progression and a poor overall prognosis.

The FDA’s Breakthrough Therapy Designation is intended to expedite the development and review of a drug candidate that is planned to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints.